Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 09:31AM EDT. Market open.
| Previous close | 132.27 |
| Open | 129.82 |
| Bid | 129.84 x 900 |
| Ask | 136.00 x 800 |
| Day's range | 132.07 - 132.54 |
| 52-week range | 117.58 - 212.00 |
| Volume | |
| Avg. volume | 866,400 |
| Market cap | 16.013B |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
- Zacks
Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View
Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.
- Zacks
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Lags Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of -3.63% and 12.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2022 Yahoo. All rights reserved.
